Annalisa Di Risio

Title: Annalisa Di Risio: Innovator in Antibody Development

Introduction

Annalisa Di Risio is a prominent inventor based in Chieti, Italy. She has made significant contributions to the field of biotechnology, particularly in the development of innovative antibodies targeting tumor-related antigens. Her work is crucial in advancing cancer treatment methodologies.

Latest Patents

Annalisa holds a patent for an Endosialin-binding antibody. This invention relates to the generation of an antibody that specifically recognizes and binds Endosialin, a cell surface antigen characteristic of tumor pericytes and cells of tumor stroma. The antibody has the ability to become internalized in Endosialin-expressing cells and to block the activation of MAPK in PDGF-stimulated human pericytes. Additionally, it can block angiogenesis induced by LGALS3BP, a known Endosialin interactor, and inhibit tumor growth both alone and in combination with a humanized antibody against LGALS3BP in human osteosarcoma xenografts. Furthermore, upon conjugation of the humanized version of the anti-Endosialin antibody with a duocarmycin derivative, the resulting antibody-drug conjugate displays potent and antigen-dependent in vitro tumor cell cytotoxicity and effective antitumor efficacy in vivo.

Career Highlights

Annalisa is currently associated with Fusion Pharmaceuticals Inc., where she continues her groundbreaking work in antibody development. Her innovative approach and dedication to research have positioned her as a key figure in the biotechnology sector.

Collaborations

Annalisa collaborates with talented professionals in her field, including Emily Capone and Stefano Iacobelli. These collaborations enhance the research and development efforts at Fusion Pharmaceuticals Inc.

Conclusion

Annalisa Di Risio's contributions to antibody development represent a significant advancement in cancer treatment. Her innovative work continues to inspire and pave the way for future breakthroughs in biotechnology.